Found 4 articles for: "Tofacitinib"
Open-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)
April 2023 | Volume 22 | Issue 4 | Features | 425 | Copyright © April 2023
Citation: Alsukait S, Learned C, Rosmarin D. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with Discoid Lupus Erythematosus (DLE). J Drugs Dermatol. 2023;22(4)...
Read MoreRefractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
December 2022 | Volume 21 | Issue 12 | Case Reports | 1366 | Copyright © December 2022
Background: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA)...
Read MoreA Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis
October 2022 | Volume 21 | Issue 10 | Editorials | 1133 | Copyright © October 2022
Dermatomyositis (DM) is an autoimmune myopathy with characteristic dermatologic features.1 Tofacitinib is an immunomodulator with proven efficacy against numerous immune-mediated disorders,...
Read MoreSuccessful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
July 2018 | Volume 17 | Issue 7 | Case Reports | 800 | Copyright © July 2018
Alopecia areata is an autoimmune disease involving the hair follicle with a chronic, relapsing course. Tofacitinib...
Read More
